Shares of Cochlear, an Australian hearing implant manufacturer, plummeted by nearly 41% on Wednesday in what marked the company’s steepest single-day decline on record. The dramatic drop followed the medical device maker’s announcement of severely reduced annual profit projections due to challenging market conditions and disruptions stemming from ongoing Middle East conflicts.
This earnings warning joins a growing list of similar announcements from companies across Australia and New Zealand, as the effects of Middle East warfare continue to disrupt global supply chains, drive up inflation, weaken consumer confidence, and alter corporate investment patterns.
The hearing implant specialist now projects underlying net profits between A$290 million and A$330 million ($207.61 million-$236.25 million) for the 2026 fiscal year, representing a dramatic reduction from earlier estimates of A$435 million to A$460 million.
This revised forecast falls significantly below market expectations, with the midpoint missing analyst consensus projections of A$402.5 million by a substantial margin.
Cochlear’s stock price, which previously held the distinction of being among the most expensive on Australia’s stock exchange, dropped 40.7% to close at A$99.58, marking its lowest closing value since March 2016.
According to the company, market demand in developed nations has weakened considerably since January due to limited hospital capacity, reduced medical referrals, and declining consumer confidence. These factors have particularly impacted the United States market, where patients are postponing elective medical procedures and surgical interventions.
“Tough times for developed world insurers translate to volume delays, at the very least, the question for us and the market is whether the issues outlined today are structural,” Jefferies analysts noted in their research report.
“Our recent discussions with U.S. Cochlear implant clinics highlight that public and private health insurers are under increasing pressure, leading to volume delays for providers,” the analysts added.
While demand in emerging markets has remained relatively stable, Cochlear warned that Middle East conflicts are likely to result in canceled orders and potential delivery delays to certain regions.
The company anticipates second-half sales growth of just 2% to 6% on a constant currency basis, reflecting the combined impact of weakened developed market performance and Middle East uncertainties.
Cochlear also disclosed potential financial impacts including up to A$10 million in receivables provisions for the year and approximately A$25 million in second-half losses due to Australian dollar strength against other currencies.
